Phase 1b trial of CRS-207, immunotherapy vaccine, with chemotherapy for malignant pleural mesothelioma

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, David Carbone, MD, PhD, from The Ohio State University Wexner Medical Center, Columbus, OH, discusses a phase 1b trial of the anti-mesothelin vaccine CRS-207 plus chemotherapy as frontline treatment for malignant pleural mesothelioma.